Brief: Briacell Initiates Pivotal Phase 3 Study Of Bria-Imt™ In Advanced Metastatic Breast Cancer
03/10/2023 14:17
Oct 3 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL INITIATES PIVOTAL PHASE 3 STUDY OF BRIA-IMT™ IN
ADVANCED METASTATIC BREAST CANCER
* BRIACELL THERAPEUTICS - SEES RANDOMIZED PIVOTAL PHASE 3
STUDY TO
ENROLL 354 PATIENTS IN EITHER BRIA-IMT COMBINATION OR
PHYSICIAN'S CHOICE THERAPY
* BRIACELL THERAPEUTICS CORP - POSITIVE RESULTS OF PIVOTAL
PHASE 3
STUDY COULD RESULT IN FULL APPROVAL AND MARKETING AUTHORIZATION
FOR BRIA-IMT
Source text for Eikon: ID:nGNX40LbSD
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study